Ritter Pharms

RTTR NASDAQ
1.000
-0.040
-3.85%
Closed 16:00 08/23 EDT
Open
1.030
Prev Close
1.040
High
1.039
Low
0.9900
Volume
99.38K
Avg Vol (3M)
247.45K
52 Week High
2.560
52 Week Low
0.4700
% Turnover
1.05%
Market Cap
9.43M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers Ritter Pharms RTTR stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Ritter Pharmaceuticals, Inc. develops therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company's segment is focusing on the development and commercialization of RP-G28. The Company conducts human gut health research by exploring metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into applications intended to have impact on a patient's health. The Company's compound, RP-G28, is under development for the treatment of lactose intolerance. The Company has completed a Phase IIa clinical trial of its product candidate, RP-G28, an orally administered oligosaccharide. RP-G28 is designed to stimulate the growth of lactose-metabolizing bacteria in the colon. The Company has not generated any revenues.
MORE >

Recently

Name
Price
%Change